No Data
Express News | Reported Earlier, HUTCHMED Publishes Phase III Sovleplenib Results, 48.4% Response Rate In ITP Patients Versus 0% In Placebo Group
Hutchmed (China) announced that the results of the phase III ESLIM-01 study were published in The Lancet Haematology.
On June 17th, HutchMed (China) (00013.HK) announced that the results of the ESLIM-01 Phase III study of Sovleplenib (HMPL-523) for adults with primary immune thrombocytopenia were published in The Lancet Haematology. Additional details and subgroup results of this study were also presented in the form of an oral report and two posters at the European Hematology Association (EHA) 2024 annual meeting on June 14th. Sovleplenib is a type of
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that results from ESLIM-01, HUTCHMED's Phase III trial of sovleplenib (HMPL-523), in adult patients with primary immune thrombocytopenia ("ITP") in China, were published in The Lancet Haematology.
Open source securities: first-time buy rating for hutchmed (china) (00013), entering the global harvest period in the solid tumor field.
According to the research report released by Kaiyuan Securities, bullish-rated Hutchmed (China) for the first time, expecting a net income attributable to shareholders of -648 million/18 million/1.131 billion yuan from 2024 to 2026. Fruquintinib has been approved for marketing in the United States in 2023 and is commercially sold overseas by Takeda Pharmaceutical. Multiple indications of several products in the pipeline are expected to be gradually approved in the global market in the coming years, and the company has entered the global harvest period. The bank is bullish on the company's long-term development. The pipeline is calculated based on the already approved and expected pipeline.
HK stocks abnormal | Hutchmed (China) Medicine (00013) rose more than 5%. The company recently launched the HMPL-506 phase I clinical trial for hematologic malignancies.
Hutchmed (China) (00013) rose more than 5%, as of press time, up 5.11%, reported HKD 29.85, with a turnover of HKD 33.2161 million.
Hutchmed Begins Phase 1 Trial of Potential Treatment for Acute Myeloid Leukemia
Hutchmed (HCM) said late Thursday it has begun a phase 1 trial of its drug candidate, HMPL-506, which is intended to treat patients with hematological malignancies, such as acute myeloid leukemia. The
Prasadssvga : Do you think is ready?
Momentum TraderOP Prasadssvga: Already Bo from pivot. Don’t chase high!